An interventional study of Point-of-Care high-sensitivity troponin testing in Acute Coronary Syndromes, sponsored by KU Leuven. Active, not recruiting at 1 site in Belgium. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-21.
Sponsored by KU Leuven · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 50 studies in Acute Coronary Syndrome with a site in Belgium — 4 open to participants now, 5 under way, none of them phase 3. Acute Coronary Syndrome · Belgium.
Among the 50 studies in Acute Coronary Syndrome with a site in Belgium, this one is the 27th largest by planned enrollment of the 43 interventional ones that give a count, is one of 4 that started in 2025, is one of 16 with no phase, and was the 47th registered.
1,491 studies on the registry are indexed under Acute Coronary Syndrome; 272 are open to participants now.
Browse Acute Coronary Syndrome studies →4 of the 50 studies in Acute Coronary Syndrome with a site in Belgium are open now. Recruiting first, the newest first:
Universitair Ziekenhuis Brussel · Sites in Belgium
Ages 30+
St. Antonius Hospital · Sites in Belgium, Netherlands
Ages 18+
CoreAalst BV · Sites in Belgium, China, France and 5 more countries
Ages 18–85
Aarhus University Hospital Skejby · Sites in Belgium, Denmark, Estonia and 9 more countries
Ages 18+
A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →
Of the 195 Acute Coronary Syndrome studies recruiting now, 144 (74%) set no upper age limit and 19 (10%) stop at 75 or younger; 15 take children under 18; 15 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
50 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 4 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,552 is above the median of 200 across 868 interventional studies indexed under Acute Coronary Syndrome.
Median enrollment 2,700 across the 43 interventional studies, 1,453 across the 7 observational. Of the 38 that completed or were terminated, 16 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
28 of 50 have an industry lead sponsor. The 10 most frequent:
KU Leuven is the lead sponsor of 373 studies on the registry; 65 are open to participants now.
KU Leuven has 2 studies filed under Acute Coronary Syndrome — fewer than ten, so there is no comparison to draw.
3 of the studies in Acute Coronary Syndrome with a site in Belgium that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06845826KU LeuvenPoint-of-Care Troponin Testing in the Emergency Department | 2026-11-30 |
| NCT07192965Universitair Ziekenhuis BrusselECG-less Coronary Computed Tomography Angiography in the Management of Patients Presenting With High-troponin Chest Pain | 2027-09 |
| NCT04436978St. Antonius HospitalWhat is the Optimal Antithrombotic Strategy in Patients With Atrial Fibrillation Undergoing PCI? | 2027-10-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 50 studies in Acute Coronary Syndrome with a site in Belgium, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this study is to evaluate whether a POC-guided testing strategy to exclude non-ST elevation myocardial infarction (NSTEMI) in acute chest pain patients presenting at the emergency department (ED) can result in a shorter length of stay compared to the routine central laboratory testing strategy. Currently, most often two high-sensitivity troponin (hs-cTn) tests are required for exclusion of NSTEMI, and central laboratories are struggling to achieve the recommended turnaround time of 60 minutes. Novel POC hs-cTn testing technology can provide results in minutes, potentially reducing the ED length of stay. This may lead to a reduction in ED crowding, which is a growing worldwide healthcare problem, resulting in poorer patient outcomes. This study may therefore improve patient burden, ED staff workload, and lead to more efficient expenditure of healthcare resources.
We will perform a prospective, cross-sectional, interventional, single-center, open label, randomized trial.
All consecutive patients older than 18 years and younger than 75 years presenting at the UZ Leuven emergency department with chest pain or chest pain-equivalent symptoms suspected of an acute coronary syndrome (ACS) will be invited to participate in the study. After informed consent patients will be randomized into the point-of-care testing (POCT) group or the usual care group. Patients in the POCT group will undergo the novel POC test-guided strategy. In the POC strategy the first hs-cTnI test shortly after admission to the ED will be performed on the POC Atellica VTLi. The second test will be performed with the usual central laboratory hs-cTnT test. Patients in the usual care group will undergo the usual testing strategy with one or two hs-cTnT tests performed in the hospital's central laboratory.
Testing strategy Triage nurses, ED registration staff, or the treating physicians will identify eligible patients after which recruitment will be performed by the study collaborator(s). After informed consent patients will be randomized into the point-of-care testing (POCT) group or the usual care group. All patients first undergo usual work-up, including clinical history and examination, and an ECG, thereby identifying clinically unstable patients and patients with signs of a STEMI (exclusion criteria), and identifying patients who need further exclusion of a NSTEMI by hs-cTn testing. Patients in the POCT group will undergo the POC test-guided strategy with the Atellica VTLi. In the POC strategy the first hs-cTnI test shortly after admission to the ED will be performed on the POC Atellica VTLi. This represents a novel testing strategy. The second test will be performed with the usual central laboratory hs-cTnT test. Patients in the usual care group will undergo the traditional central laboratory hs-cTnT testing strategy. As a safety back-up in all patients in the POCT group, usual central laboratory high-sensitivity troponin testing will be performed as well. Only one additional blood sample tube is required to perform the POC test. The test requires a whole blood or plasma sample of 30-100 μL, which will be collected in a lithium-heparin tube. The sample can be safely transferred from the blood tube to the test cartridge with an accompanying transfer device designed by Siemens Healthineers at the point of care. The left-over material of the blood sample after POC testing will be transferred to the hospital's central laboratory to assess for the presence of haemolysis and its impact on the POC test results.
Management and treatment decisions The troponin test results will be available to the treating ED physicians, immediately influencing medical management decisions. The physicians will be trained correctly to use the POC device within the POC test-guided strategy. The Atellica VTLi will be connected to the laboratory information management system so the test result will be available in the patient's electronic medical health record (KWS). Patients in the POCT group presenting with chest pain after more than 3 hours of onset of the current episode of symptoms, no signs of ischaemia on ECG and with an hs-cTnI value below 7 ng/L on the Atellica VTLi will be considered at very-low risk for NSTEMI and can be considered for early ED discharge.(22) Patients with an hs-cTnI value higher than 60 ng/L are considered at high risk for NSTEMI and should be considered for immediate hospital admission and further treatment. Patients with an hs-cTnI value between 7 ng/L and 60 ng/L are considered at intermediate risk of NSTEMI and should be considered for a second hs-cTnT test within the standard UZ Leuven protocol. As a back-up in all patients in the POCT group an additional central laboratory hs-cTnT test will be performed, as POC test failures are currently seen in 7% of performed test, and since the test at admission is required to calculate the one-hour delta. The treating physician will be blinded to this test result to avoid waiting for a second confirmation of the POCT result and thereby compromising the ED length of stay. The result however will be communicated by the clinical laboratory to the treating physician in case of marked discrepant test results: if the result on the POC test is below 7 ng/L, allowing for rule-out of NSTEMI, while the result on the central laboratory test is > 14 ng/L, indicating a higher probability of NSTEMI. If the patient has already been discharged by the time the back-up test is communicated to the treating physician, the patient will be contacted to return to the ED for further examinations and further treatment if necessary. Re-admitted patients will be managed according to routine clinical care, and no additional study-related interventions will be applied. In the case of a negative POC test result, and a central lab hs-cTnT value between 5 and 14 ng/L, we deem the probability of an NSTEMI very low, allowing for ED discharge without further treatment. In case of a second test after 1 hour, the 0h hs-cTnT and the 1h hs-cTnT test will be reported together as usual through the electronic medical record, to allow for the assessment of a change in troponin values.
All final medical management decisions are at the discretion of the treating physician, so he or she is allowed to deviate from the proposed algorithm according to their clinical judgement. Other life-threatening causes of chest pain such as pulmonary embolisms, heart failure or pneumonia may be considered next to ACS. If the treating physician deems that NSTEMI is not sufficiently ruled out after a negative POC hs-cTnI test or other conditions should be further excluded, he or she is free to perform additional investigations or to admit the patient to a hospital ward. Patients in the usual care group will undergo usual central laboratory hs-cTnT testing.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
care as usual: central laboratory troponine testing
To establish in a randomized interventional controlled trial whether a novel POC test-guided strategy in acute chest pain patients in the ED results in a reduced length of stay compared to the usual central laboratory testing strategy when managing patients with a suspicion of NSTEMI
Device: Point-of-Care high-sensitivity troponin testing
To establish in a randomized interventional controlled trial whether a novel POC test-guided strategy in acute chest pain patients in the ED results in a reduced length of stay compared to the usual central laboratory testing strategy when managing patients with a suspicion of NSTEMI
Length of stay at emergency department
with a tracking bracelet we measure the time of presentation until discharge of the patient in the emergency department
Time frame: Hours: 24
30-day MACE
To assess the secondary endpoint of major adverse cardiac events (MACE), the final diagnosis after the ED visit will be extracted from the electronic hospital patient record. For patients discharged home from the ED, thirty days after discharge the patient's hospital record will be checked and the patient's regular GP will be contacted to confirm if any major adverse cardiac events occurred.
Time frame: Day: 30
Degree of user friendliness: questionnaires and qualitative think aloud sessions
user friendliness of the POC Atellica VTLi hs-cTnI test device: questionnaires and think aloud sessions for qualitative research
Time frame: Hours: 24
Phyisican adherence
The physician will be asked to indicate whether the proposed testing strategy was followed or whether he or she deviated from it and the reason why, to assess the physician adherence to the testing strategy.
Time frame: Hours: 24
Patient satisfaction
Patient satisfaction with the POC test-guided strategy will be assessed as an exploratory endpoint by contacting the patients after discharge (at day 7 baseline visit) and taking questionnaires on how they experienced their care. The Short Assessment of Patient Satisfaction (SAPS-)questionnaire will be used, extended with open questions and specific questions to our current study. Scoring is done by first reversing the scores for items #1, #3, #5, #7, and then summing all scores. The score range is from 0 (extremely dissatisfied) to 28 (extremely satisfied)
Time frame: Day: 7
Comparison of POC and central laboratory hs-cTnI testing, and central laboratory hs-cTnT testing
Congruence between POC and central laboratory hs-cTnI testing, and central laboratory hs-cTnT testing: assessment of agreement in terms of diagnostic accuracy and correlation
Time frame: Hours: 24
External validation of clinical prediction models Heart score + T-MACS score
Discrimination (AUC, O:E ratio, sensitivity and specificity), calibration and clinical utility (net benefit) of Heart score + T-MACS score
Time frame: after obtaining the sample size
Plan to share: Undecided
No publications or documents are linked to this record.
Started Jun 2025 (actual). Primary completion is estimated for Nov 2026, 17 months after the start.
Of 213 non-industry interventional studies with no phase under Acute Coronary Syndrome, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 46. This study's planned 17 months is below that.
Counting every sponsor, half of 228 studies reached it within 34 months; a quarter within 17 and three quarters within 46.
Primary completion moved once since we started tracking on Sep 25, 2026: Jun 2026 → Nov 2026, on Oct 21, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.